XRAY is the ticker symbol for DENTSPLY SIRONA Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks XRAY with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is XRAY a good stock to buy?

13F Pro's AI ranking engine scores XRAY at 39.9/100, ranked #2,115 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for XRAY is available at https://13fpro.ai/company/XRAY. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source XRAY data?

All DENTSPLY SIRONA Inc. fundamentals and ownership data come directly from SEC EDGAR. DENTSPLY SIRONA Inc. files with the SEC under CIK 818479. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

DENTSPLY SIRONA Inc. XRAY

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,115 of 2,925

Why it scores 40 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$898.00M

Quarter to Jun 30

Net income

$37.00M

Quarter to Jun 30

Free cash flow

$55.00M

Quarter to Jun 30

Operating margin

9.1%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$2.40B total

BlackRock, Inc.

$283.40M+38.7%

FULLER & THALER ASSET MANAGEMENT, INC.

$134.72M-0.7%

VANGUARD PORTFOLIO MANAGEMENT LLC

$124.98M+11.9%

AQR CAPITAL MANAGEMENT LLC

$110.18M+163.8%

STATE STREET CORP

$98.52M+28.2%

VANGUARD CAPITAL MANAGEMENT LLC

$96.00M+0.5%

LAZARD ASSET MANAGEMENT LLC

$87.74M+23.1%

ARIEL INVESTMENTS, LLC

$85.16M+25.7%

Southpoint Capital Advisors LP

$74.27M-30.0%

COOKE & BIELER LP

$73.51M-11.2%

GEODE CAPITAL MANAGEMENT, LLC

$59.96M+47.8%

Invenomic Capital Management LP

$52.09M+11.8%

EDMOND DE ROTHSCHILD HOLDING S.A.

$47.78M+7.8%

JUPITER ASSET MANAGEMENT LTD

$47.69M+457.0%

Allianz Asset Management GmbH

$40.57M+29.8%

MARSHALL WACE, LLP

$40.32M-15.7%

PARADIGM CAPITAL MANAGEMENT INC/NY

$39.77M+25.9%

ARMISTICE CAPITAL, LLC

$38.96M+22.4%

DIMENSIONAL FUND ADVISORS LP

$36.72M-2.8%

D. E. Shaw & Co., Inc.

$31.69M+22.8%

Neuberger Berman Group LLC

$31.22M+54.6%

BANK OF AMERICA CORP /DE/

$31.00M+20.1%

Brickwood Asset Management LLP

$30.93M+1.5%

Ranmore Fund Management Ltd

$27.59MNew

NORTHERN TRUST CORP

$27.49M+47.6%

See all 379 institutional holders →

What's Driving XRAY's Business? Latest 10-Q Breakdown

25/25 datapoints verified

AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue declined 4% YoY to $898M as Byte divestiture and lower OIS volumes offset tariff refund gains; net income swung to $37M profit from $45M loss.

Biggest Revenue Drivers

Essential Dental Solutions$376M-2.7% YoY

Lower volumes in EMEA and increased promotional activity in Americas, partially offset by higher preventive product volumes in Americas.

Connected Technology Solutions$239M-1.5% YoY

Lower CAD/CAM volumes in Americas and unfavorable pricing in EMEA, partially offset by higher volumes in APAC.

Biggest Revenue Drivers

Total revenue: $898M-4.1% YoY

Essential Dental Solutions$376M-2.7% YoY

Lower volumes in EMEA and increased promotional activity in Americas, partially offset by higher preventive product volumes in Americas.

Connected Technology Solutions$239M-1.5% YoY

Lower CAD/CAM volumes in Americas and unfavorable pricing in EMEA, partially offset by higher volumes in APAC.

Orthodontic and Implant Solutions$197M-13.2% YoY

Absence of Byte business net sales in 2026 and lower volumes of implant products.

Wellspect Healthcare$86M+7.1% YoY

Higher product volumes in EMEA and benefit from new product introductions.

Largest Expense Items

Selling, general, and administrative expenses$364M+6.7% YoY

Increase driven by unfavorable foreign currency impacts, partially offset by restructuring benefits and lower professional services costs.

Cost of products sold$405M-9.2% YoY

Lower volume-related costs, partially offset by unfavorable product mix and tariff expenses, benefited by tariff refunds and favorable currency.

Research and development expenses$45M+20.3% YoY

Increased allocation to DS Core platform expansion and accelerated key projects across all segments.

Margins: Gross margin improved 250 bps YoY to 54.9% of sales, driven by $44M tariff refunds and favorable FX impacts, despite headwinds from lower volumes and unfavorable product mix. Operating margin expanded significantly with restructuring charges declining and tariff gains offsetting volume deleverage.

Watch Items from the Filing

Byte divestiture eliminated Q2 OIS segment revenue; no quantified impact disclosed but described as material absence in Americas.
$44M tariff refund received in Q2 2026 benefited gross profit and cash flow; future tariff policy impacts remain uncertain with ongoing court challenges.
OIS segment adjusted operating income fell 53% YoY to $21M; CTS segment turned negative at $(2)M from $12M, signaling margin pressure beyond revenue decline.
2026 restructuring plan targeting $120M annualized cost savings; $57M charged through June 30 with $60–65M total expected charges mostly in 2026–2027.
CAD/CAM and imaging distributor inventory at June 30 remain below historical averages; future sales timing uncertain as distributors restock.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Debt/Equity

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/XRAY

Earnings Per Share

13fpro.ai/company/XRAY

Loading ratio trend…

DENTSPLY SIRONA Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$3.7B	$-598.0M	-11.5%
FY 2024	10-K	$3.8B	$-910.0M	-23.2%
FY 2023	10-K	$4.0B	$-132.0M	-2.1%
FY 2022	10-K/A	$3.9B	$-950.0M	-23.9%
FY 2021	10-K/A	$4.2B	$411.0M	14.4%
FY 2020	10-K	$3.3B	$-73.0M	-0.1%

About DENTSPLY SIRONA Inc. (XRAY): stock profile, AI score and financials

DENTSPLY SIRONA Inc. (XRAY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XRAY at 39.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,115 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (16.4) and balance sheet strength (17.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), DENTSPLY SIRONA Inc. reports quarterly revenue of $898.0M, net income of $37.0M, an operating margin of 9.1%. Top institutional holders of XRAY by reported 13-F value include BlackRock, FULLER & THALER ASSET MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. XRAY trades on the Nasdaq exchange and files with the SEC under CIK 818479. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XRAY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DENTSPLY SIRONA Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 818479 →

DENTSPLY SIRONA Inc. XRAY

Top Institutional Holders

What's Driving XRAY's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

XRAY key financials by period

XRAY insiders

Congress trading in XRAY

About DENTSPLY SIRONA Inc. (XRAY): stock profile, AI score and financials

DENTSPLY SIRONA Inc. XRAY

Top Institutional Holders

What's Driving XRAY's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

XRAY key financials by period

Companies similar to XRAY

XRAY insiders

Congress trading in XRAY

About DENTSPLY SIRONA Inc. (XRAY): stock profile, AI score and financials